Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex for Psychiatric Conditions

Yes, there are some yet-obscure and incomplete indications that Anavex sigma-1 receptor agonists might yield beneficial treatments for psychiatric conditions, from various forms of depression to schizophrenia.

If any of these involve poorly-folded proteins (enzymes) controlling psychological processes, an Anavex involvement or solution is plausible. Anavex sigma-1 receptor agonists are known to facilitate proper protein folding in neurons where mitochondria and endoplasmic reticula have become disconnected. These mitochondrial malfunctions appear to be at the root of a host of human diseases. Presently, the company is targeting just three; Alzheimer’s disease, Parkinson’s disease, and the rare Rett syndrome.

Anavex 2-73 has a number of advantages over other psychotropic medications. First, it is administered orally, without injection.

But much better, and unlike the majority of existing psychotropics, it has virtually no side effects.

The developing story of Anavex treating the three diseases presently in the Anavex spotlight may eventually expand to a diversity of disease types, beyond the neurodegeneratives presently being addressed.

Anavex Life Sciences Corp is likely to be bigger, have more medical impact than presently anticipated. The company’s therapeutic technologies are unique and revolutionary. Nothing else like them in pharmacies today. Yet to be proven, of course.

We are watching closely.